LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Accueil・Liste d'Actions・Design Therapeutics Inc

Design Therapeutics Inc

Fermé

10.98 -0.27

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

10.98

Max

11.26

Chiffres clés
By Trading Economics
Revenu	-1.6M -18M
BPA	-0.29
Employés	54
EBITDA	-1.5M -20M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+78.67% upside

Dividendes
By Dow Jones
Prochains Résultats	5 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	98M 898M
Ouverture précédente	11.25
Clôture précédente	10.98

Design Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 mai 2026, 23:46 UTC

Market Talk

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24 mai 2026, 23:45 UTC

Market Talk

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24 mai 2026, 23:42 UTC

Market Talk

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24 mai 2026, 23:34 UTC

Market Talk

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24 mai 2026, 23:11 UTC

Market Talk

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24 mai 2026, 22:26 UTC

Acquisitions, Fusions, Rachats

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24 mai 2026, 22:25 UTC

Acquisitions, Fusions, Rachats

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24 mai 2026, 22:25 UTC

Acquisitions, Fusions, Rachats

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24 mai 2026, 22:24 UTC

Acquisitions, Fusions, Rachats

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24 mai 2026, 22:24 UTC

Acquisitions, Fusions, Rachats

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24 mai 2026, 22:23 UTC

Acquisitions, Fusions, Rachats

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24 mai 2026, 22:23 UTC

Acquisitions, Fusions, Rachats

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24 mai 2026, 22:11 UTC

Market Talk

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24 mai 2026, 22:04 UTC

Market Talk

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23 mai 2026, 08:20 UTC

Market Talk

Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

23 mai 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22 mai 2026, 21:10 UTC

Résultats

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22 mai 2026, 20:50 UTC

Market Talk

Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

22 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 mai 2026, 19:47 UTC

Résultats

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 mai 2026, 19:17 UTC

Market Talk

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 mai 2026, 19:10 UTC

Market Talk

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 mai 2026, 18:54 UTC

Market Talk

Global Equities Roundup: Market Talk

22 mai 2026, 18:54 UTC

Market Talk

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 mai 2026, 18:38 UTC

Market Talk

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 mai 2026, 18:35 UTC

Acquisitions, Fusions, Rachats

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 mai 2026, 18:09 UTC

Market Talk

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 mai 2026, 17:58 UTC

Market Talk

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Comparaison

Variation de prix

Design Therapeutics Inc prévision

Objectif de Prix

By TipRanks

78.67% hausse

Prévisions sur 12 Mois

Moyen 19.6 USD 78.67%

Haut 22 USD

Bas 15 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

Achat

Maintien

Vente

Basé sur 6 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.